Bard Peripheral Vascular, Inc. is a NASDAQ listed company (“BCR”) headquartered in Tempe, Arizona, and owned by Becton Dickinson (NASDAQ: “BDX”).
It is a global leader in the development, manufacturing and marketing of innovative, life-improving and medical technologies.
Its TRUE® Flow Valvuloplasty Perfusion and TRUE® DILATATION Balloon Valvuloplasty Catheters were designed to provide precise, reliable and controlled dilatations during TAVI and BAV procedures.
The TRUE® FLOW Valvuloplasty Perfusion Catheter uses a unique eight-chamber inflation system to allow continuous cardiac blood flow through the completely inflated balloon.
The balloon was designed to provide low hemodynamic resistance; it is the only balloon providing continuous cardiac blood flow independent of the heart’s rhythmic state.
With its fiber-based shell the TRUE® FLOW balloon is rupture resistant, stays true to size and exhibits less than 1% stretch between nominal and rated burst pressure.
TRUE® DILATATION Balloon
The TRUE® DILATATION Balloon was specifically designed for BAV and TAVI procedures and supports precise, controlled and reliable dilatations.
It is fabricated from KEVLA (mesh-like material) and carbon-coated which makes the balloon highly resistant to ruptures, punctures and tears.
Fiber reinforcements precisely limit the maximum balloon diameter to the labeled size, while allowing flexible conformance to anatomical variations. The TRUE® DILATATION Balloon redefines the category, offering diameter control within a range of 1.5%.
It inflates and deflates 2 to 3 times faster than competitors’ balloons, considerably minimizing ischemia time.
These innovative closure devices are inserted via a catheter through the femoral vein into the venous vessel system and offer a safe and reliable method for the minimally invasive treatment of atrial septal defects (ASD), patent foramen ovale (PFO) and left atrial appendage (LAA).
Ultrasept devices are inserted via a catheter in an approximately 30-minute-long procedure by an interventional cardiologist; they can all be deployed without the need for open-heart surgery. This means that the majority of patients who are admitted in the morning may already return home the next day and do not have to go through the lengthy recovery process frequently following open-heart surgery.
The Ultrasept occluder was developed for the catheter-controlled transvenous closure of patent foramen ovale (PFO).
The occluder consisting of two articulating sails is easily deployed due to its flexible orientation and creates an ultra-low profile within the septum.
When designing the occluder, special focus was put on reducing metal and other foreign materials to a minimum. Patients with an existing nickel allergy, for example, can be treated with the Ultrasept occluder without incurring adverse allergic reactions.
The Ultraseal occluder was developed for the catheter-controlled transvenous closure of the left atrial appendage (LAA).
The joint in the center of the occluder is movable in all directions and allows for precise and easy positioning and conformance to various atrial appendage anatomies. As the occluder can be repositioned several times, a secure LAA closure is guaranteed.
The principle of minimal metal usage in the occluder applies to this implant, too.
INNOWI guidewires are mainly used to support and enhance TAVI procedures.
INNOWI as well as INNOWI SX are primarily defined by their special segmentation into three parts with different grades of stiffness. These exactly match the anatomical features and therefore provide ideal support for interventional cardiologists.
The wire shaft starts with a very hard segment followed by the yielding segment which lies in the aortic arch and the atraumatic very soft curvature positioned in the ventricle.
The only difference between INNOWI and INNOWI SX is the stiffness of the segment which lies in the aortic arch. Both wires are available in a small and large curvature.
Essential Medical, Inc. is a privately lead medical devices company headquartered in Exton, Pennsylvania, which was acquired by Teleflex Medical, Inc. (NASDAQ: “TFX”) in December 2018.
Their novel MANTA vessel closure system was developed for the occlusion of large puncture sites. All puncture sites of diagnostic and interventional heart catheter procedures through the femoral artery within a range of 10F to 25F O.D. can be closed with this system.
MANTA 18F System
The 18F System is intended for closures with an outer diameter of 18F to 25F. It is mainly used in transcatheter aortic valve implantation (TAVI) procedures.
Get in touch
+49 (0) 171 371 0024